Health

Pauline Latham Excerpts

Tuesday 20th December 2011 Commons Chamber

[Pauline Latham (Mid Derbyshire) (Con)]

I rise today to talk about the east midlands cancer drugs fund, because I have had many dealings with this organisation, none of them very satisfactory. The last such dealing was today, although I would like to start my story, as it were, with my attempts over some months to get Avastin for a constituent of mine. She has already funded more than £60,000-worth of the drug herself. She has sold her car, used her retirement money and sold her heirlooms, and she now has no money left, yet still the east midlands cancer drugs fund will not give her Avastin, because—it says—there is no proof that it works. However, she is living proof that it works, because she has been taking it for two years. It costs her £1,600 every three weeks, and nobody can afford that sort of money. I also have another affected constituent, whom I saw on Friday, but because she is smaller than the other lady it costs her only £1,300—a real snip.

I am appalled at the way those patients are being treated. The reason why we are talking about a second-line treatment is that the first line failed. However, those patients do not choose the first line, because they rely on the consultants to give them the right drug in the first place. When that drug fails, the consultant puts the patient on a drug that works, but in this case, those in the east midlands are not allowed to have that drug funded by the NHS. However, patients can have it funded in the west midlands, the north-east and East Anglia, along with four other trusts.

I first wrote to the east midlands cancer drugs fund about this case on 28 September. Hon. Members should remember that it is supposed to reply within 10 working days, but in this case it did not. As Avastin is not a priority drug, and as my constituent is not a priority person, the fund will reply at its leisure. I wrote on 28 September, but the first I heard from the fund was on 4 November, when, after pushing the organisation, I received a letter from the medical director of NHS Midlands and East, which said that that body would have the ultimate view on whether the drug could be prescribed. The letter also said:

“I can, however, ask the Clinical Panel to review”

my constituent’s

“case and have asked the Clinical Lead to convene an urgent meeting. This meeting will consider clinical effectiveness evidence in accordance with the principles underpinning the East Midlands Cancer Drugs Fund. I will also ask the Panel to reconsider the evidence in the context that other parts of the country have reached a different conclusion regarding the efficacy of avastin as a second line treatment. The Chair of the Clinical Panel will inform me of the outcome of its deliberations”.

That was on 4 November, after I had written on 28 September. That panel has not met. Why not? Because those responsible cannot get the right people together. They convened a meeting, but they asked the wrong people to come to it, so they decided to abandon that. Eventually, after several e-mails, on 10 and 14 November, they let me know that they were urgently considering a meeting, but had not had one yet, and they still have not. Apparently, the people who make the decisions are informing them by e-mail what they think of this case—everything is being reviewed by e-mail.

It is getting close to Christmas, as we are all aware. On 30 November I was told that I would hear by the end of that week. I have not heard anything. Now I am told that I will hear by the end of this week. This is completely and utterly unacceptable for my two constituents, who could die because of the irresponsible and inefficient way in which the organisation works. Fortunately, they are not doing so; they are getting good treatment, and both of their tumour levels have decreased from 40 to 5 while using that drug. That shows that it works, and I do not understand the reluctance of the east midlands cancer drugs fund to prescribe it.

[Jo Swinson (East Dunbartonshire) (LD)]

I thank the hon. Lady for giving way, and I apologise for not being here for the beginning of her speech. I was on the telephone to the consultant of one of my constituents who is terminally ill and who would love to get ipilimumab prescribed. Unfortunately, that is not possible. Sadly for constituents in Scotland, there is no cancer drugs fund there because the Scottish Government have different priorities from those of the coalition Government here. I understand the hon. Lady’s frustration with the way in which the fund is being administered in her area, but would she at least agree that the existence of such a fund is a real benefit to people in England? I wish that that could be the case in Scotland.

[Pauline Latham]

Yes, everyone should have a cancer drugs fund, but those funds should be reactive to what works for people. If I have time, I want to talk about ipilimumab too. It is a difficult name to say, but it is also known as Yervoy. The hon. Lady should talk to the Government in Scotland and ask them to do what we are doing here in this country. They have devolved powers that were voted for by this House—and which I do not agree with—but they have them, and they must make their own decisions.

The cancer drugs fund in the east midlands is not fit for purpose. It is not working for the benefit of patients. The people involved say that they need the necessary clinical knowledge of these cases, but they already have it. The consultant has written to them, as have I, and they can see that those patients are still alive. They are still failing miserably, however, to help my two constituents, who will die if they do not get the drug. I hope that the Minister will contact those people and ask them to work more efficiently and effectively to help those patients who rely desperately on them to provide the necessary drugs.

I want briefly to talk about Yervoy, which is also known by that other name that I cannot pronounce. It is used to treat malignant melanoma. I have to declare an interest, in that my brother died of malignant melanoma 11 years ago next month, before this drug was discovered. It is the first new treatment for malignant melanoma for 30 years. More people are dying of malignant melanoma than ever before, and it is on the increase. I believe that the National Institute for Health and Clinical Excellence should recommend that people should have that drug. I have heard stories of people in their 30s with young children getting the condition, and there is no hope for their future. As a responsive listening Government, we should be ensuring that those people get the drugs that they require.